Clinical Trial Update: A Clinical Study in Patients With Chronic Idiopathic Thrombocytopenic Purpura in R788 [Phase 3]

View source ↗

Summary

Completed Phase 3 study of fostamatinib (R788) in chronic idiopathic thrombocytopenic purpura (ITP); results have been posted by sponsor Kissei Pharmaceutical.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Idiopathic Thrombocytopenic Purpura

Drugs mentioned

• Fostamatinib (fostamatinib)

Snippet

Sponsor: Kissei Pharmaceutical Co., Ltd. | Conditions: Idiopathic Thrombocytopenic Purpura | Phase 3 | Status: COMPLETED | Results posted: 2025-08-11